Opioid Litigation Clouds Loom Over Teva's Turnaround
Executive Summary
Increasing uncertainty over Teva's liability in opioid litigation is weighing on the generic drug manufacturer, even as the North American generics business stabilized in the second quarter.
You may also be interested in...
A Steady Year For The Top Tier In Pharma Ahead Of Major Upheaval
Moderate growth at Bristol-Myers Squibb and Amgen moved the two companies into the top 10 pharma ranks, based on the most recent Scrip 100 rankings, while declining growth at Gilead and Teva moved those drug makers out.
A Steady Year For The Top Tier In Pharma Ahead Of Major Upheaval
Moderate growth at Bristol-Myers Squibb and Amgen moved the two companies into the top 10 pharma ranks, based on the most recent Scrip 100 rankings, while declining growth at Gilead and Teva moved those drug makers out.
Teva Turnaround Hung Up By The Uncertain Cost Of Settling Opioid Cases
Teva's business appears to be stabilizing but the company needs to resolve outstanding opioid liability litigation. CEO Schultz said he is hopeful a national settlement framework will be finalized.